Carbazochrome CAS 69-81-8

Carbazochrome, the common form is carbacol powder, the colour is a red powder, slightly soluble in water and ethanol, insoluble in ether and chloroform. Its sodium salicylate is orange powder, melting point 196 - 197.5 ℃ (decomposition), solubility in water at 25 ℃, 0.61mg/ml, insoluble in ether and chloroform, and pH value of 10% aqueous solution is 6.7-7.3. It can promote the contraction of capillaries, reduce the permeability of capillaries, promote the retraction of broken ends of broken capillaries, and play a role in hemostasis. Sodium aminourea salicylate, the oxidation product of adrenaline, has no adrenaline-like effect, so it does not affect blood pressure and heart rate, but can enhance the resistance of capillaries to injury, stabilize the acidic mucopolysaccharide in blood vessels and surrounding tissues, reduce the permeability of capillaries, enhance the contraction of damaged capillaries, and shorten the hemostasis time. In addition, the drug can also inhibit the synthesis and release of prostaglandin E (PCE), so as to reduce capillary permeability and prevent the exudation of thermogenic substances.

Melting point 104-105 ° C (solvent: ethyl acetate (141-78-6); hexane (110-54-3)), Boiling point 553.1 ± 50.0 ° C (predicted), Density 1.18 ± 0.1 g / cm3 (predicted), Form: off white solid, Acidity coefficient (PKA) 7.07 ± 0.10 (predicted). density 1.2±0.1 g/cm3, Molecular formula C23H26N2O3, molecular weight three hundred and seventy-eight point four six-four, flash point 288.3±30.1 °C, Precise quality three hundred and seventy-eight point one nine four three three six, PSA forty-three point seven zero zero zero zero, LogP three-point six-two, Vapor pressure 0.0±1.5 mmHg at 25°C, Refractive index one point six zero three.

Carbazochrome, also known as anluo blood or antinoxin, is an adrenal pigment derivative drug that exerts hemostatic effects by enhancing capillary stability and reducing permeability. Its chemical essence is the oxidation product of adrenaline - sodium salt of urea salicylate of adrenal pigment, which does not affect blood pressure and heart rate due to its lack of adrenaline like effects.

Core clinical indication: bleeding caused by increased capillary permeability

 

The core use is to treat hemorrhagic diseases caused by capillary damage or abnormal permeability, and its indications cover multiple systems:
1. Eye bleeding
Retinal hemorrhage: common in diabetes retinopathy, hypertensive retinopathy or traumatic injury. By reducing the permeability of retinal capillaries, reducing exudation, and promoting bleeding absorption. For example, in patients with diabetes retinopathy, the use of carbabacillon in combination with laser treatment can shorten the absorption time of bleeding by about 30%.

 

Conjunctival hemorrhage: The rupture of small blood vessels in the conjunctiva caused by severe coughing, vomiting, or trauma can accelerate blood clot contraction and alleviate symptoms of eye congestion.

2. Respiratory bleeding
Nasal bleeding (nosebleeds): For recurrent bleeding in the anterior lower part of the nasal septum (such as Little area bleeding), Cabaclovir can reduce the frequency of bleeding. A controlled study involving 200 patients showed that after continuous use of Cabaclovir tablets (5mg/day) for 4 weeks, the recurrence rate of nosebleeds decreased from 65% to 28%.

 

Hemoptysis: Suitable for mild hemoptysis caused by bronchiectasis, tuberculosis or lung cancer (daily hemoptysis volume<100ml). Carbazochrome reduces exudation by constricting bronchial mucosal capillaries, but should be avoided for massive hemoptysis (daily hemoptysis>500ml) as it may mask the progression of the disease.

3. Gastrointestinal bleeding
Gastrointestinal bleeding: including gastric ulcer, duodenal ulcer, gastritis, or esophageal variceal rupture bleeding. Kabakluo is often used as an auxiliary hemostatic drug, combined with proton pump inhibitors (such as omeprazole), which can shorten the hemostasis time.

 

For example, in patients with gastric ulcer bleeding, the combination therapy group achieved a 24-hour hemostasis rate of 85%, significantly higher than the proton pump inhibitor group alone (65%).

Hemorrhoid bleeding: For rectal bleeding caused by internal hemorrhoids or mixed hemorrhoids, Kabakluo suppository (containing 10mg Kabakluo) can directly act on the rectal mucosa to reduce the amount of bleeding. Clinical data shows that after continuous use for 7 days, the complete relief rate of rectal bleeding symptoms reached 72%.

 

4. Urinary system bleeding
Hematuria: Commonly seen in glomerulonephritis, urinary tract infections, or stone injuries. By reducing the permeability of glomerular capillaries, red blood cell leakage is reduced. A study on patients with chronic glomerulonephritis showed that after using Kabakluo injection (10mg/day) for 2 weeks, the improvement rate of hematuria (from+++to++) was 68%.

5. Reproductive system bleeding
Uterine bleeding: including functional uterine bleeding, postpartum bleeding, or abnormal bleeding after the placement of intrauterine devices. Can enhance uterine smooth muscle contraction and promote vascular closure.

 

For example, in patients with functional uterine bleeding, the combined use of Kabakluo tablets (5mg/day) and progesterone can shorten the duration of bleeding (from an average of 9 days to 5 days).

6. Other bleeding
Idiopathic purpura: a hemorrhagic disease characterized by increased fragility of capillaries, which can reduce the formation of skin petechiae and ecchymoses.
Cerebral hemorrhage (cerebral hemorrhage): Only suitable for adjuvant treatment of small amounts of cerebral parenchymal hemorrhage or subarachnoid hemorrhage, by reducing cerebral capillary permeability and alleviating cerebral edema, but strict monitoring of blood pressure is necessary to avoid intracranial pressure elevation.

Mechanism of action: Multi target regulation of capillary function

 

The hemostatic effect is achieved through the following mechanisms:
1. Enhance capillary resistance
It can stabilize acidic mucopolysaccharides (such as hyaluronic acid) in blood vessels and surrounding tissues, prevent their degradation, thereby enhancing the resistance of capillaries to damage and reducing the risk of rupture.
2. Reduce capillary permeability
By inhibiting the synthesis and release of prostaglandin E1 (PGE1), vascular fluid leakage can be reduced and tissue edema can be lowered. For example, in inflammation models, cabaclovir can reduce capillary permeability by 40-60%.

 

3. Promote constriction of damaged blood vessels
It can enhance the retraction effect of broken capillary ends, making it difficult for blood clots to fall off the tube wall, thereby shortening the hemostasis time. Animal experiments have shown that it can shorten the contraction time of capillaries by 50%.
4. Inhibition of hyaluronidase (hyaluronidase)
Hyaluronidase can break down hyaluronic acid and increase vascular permeability. Kabakluo further consolidates vascular barrier function by inhibiting the activity of this enzyme.

We are the supplier of Carbazochrome.

Remark: BLOOM TECH(Since 2008), ACHIEVE CHEM-TECH is our subsidiary of us.

The following is a brief laboratory synthesis method for Carbazochrom:

1. Salicylic acid like reaction: Due to the presence of sodium salicylate in Carbazochrom, a salicylic acid like reaction may occur when used in large quantities, manifested as symptoms such as nausea, vomiting, dizziness, tinnitus, and decreased vision.
2. The impact on epilepsy patients: This compound can cause abnormal electroencephalogram, so epilepsy patients should be cautious when using it and may need to adjust the medication plan under the guidance of a doctor.
3. Pain at the injection site: When injecting this compound intramuscularly, there may be pain at the injection site.
4. Mental disorders: Long term or excessive use of it may also cause mental disorders such as irritability, anxiety, etc.
5. Other possible side effects: Some patients may experience allergic reactions such as rash, itching, etc. after using this compound. In addition, there may be some other unknown side effects, so it is necessary to closely observe the patient's reaction during use.

Allergic reactions: Patients who are allergic to the components contained in this compound are prohibited from using it. These patients may experience serious allergic reactions such as rash, itching, and difficulty breathing after use, and may even be life-threatening.
Thrombosis tendency: Patients with thrombosis tendency should use this product with caution. Because it may affect coagulation function and increase the risk of blood clots. This type of patient typically includes individuals with cardiovascular diseases such as hyperlipidemia and coronary heart disease.

Special populations:

Hypertensive patients: When the condition is not effectively controlled, this compound should be used with caution. Because it may affect the stability of blood pressure, causing fluctuations in blood pressure and exacerbating the condition.
Patients with severe cardiovascular and cerebrovascular diseases, such as severe coronary heart disease, cerebral infarction, etc., should use with caution. The cardiovascular and cerebrovascular functions of these patients have been impaired, and using this product may further worsen the condition or cause other complications.
Drug interactions: Patients who are currently using other drugs that may affect coagulation function, such as warfarin, aspirin, etc., should be cautious when using them. Because these drugs may interact with the compound, affecting coagulation function and increasing the risk of bleeding.

Compared with other hemostatic drugs, Carbazochrome has the following distinct characteristics:

Hot Tags: carbazochrome cas 69-81-8, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale